The Global Threat of AMR: Science for Intervention
Antimicrobial resistance is a serious problem that poses a serious risk to global health. Widespread use of antibiotics by health professionals and the livestock industry has resulted in an alarming global increase in the prevalence of drug-resistant bacterial infections.
Published in the journal New Microbes and New Infections and entitled “The global threat of antimicrobial resistance: science for intervention”, this paper reflects on the main points and conclusions of the debate among the main stakeholders (i.e. policy makers, public health authorities, regulatory agencies, pharmaceutical companies and the scientific community at large), which came up with a coordinated set of strategies to fight antimicrobial resistance in a multifaceted approach.
This debate was organized by B-Debate (Generalitat de Catalunya, Spain) and the Institute for Global Health of Barcelona (ISGlobal) in collaboration with the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the Spanish Network for Research in infectious diseases (REIPI). Several COMBACTE partners participated actively in the presentation of some aspects and in the in depth discussion.
Read publication
Related media library items
Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options
Data support that antibiotic aztreonam -avibactam (ATM-AVI) is effective and well- tolerated in treating infections caused by Gram-negative bacteri...
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)
Abstract Background: Data on risk factors for carbapenem-resistant Enterobacterales (CRE) with wider applicability are needed to inform preventive me...
Factors associated with recruitment success in the phase 2a study of aztreonam–avibactam development programme: a descriptive qualitative analysis among sites in Spain
ABSTRACT Objective Successful clinical trials are subject to recruitment. Recently, the REJUVENATE trial, a prospective phase 2a open-label, single-ar...